Headline: Roche Boosts Sales by 9% and Increases Dividend

Swiss pharmaceutical giant Roche reported a 9% increase in third-quarter sales, reaching 15.14 billion Swiss francs when adjusted for currency effects, surpassing analysts' estimates of 14.9 billion francs. The company announced plans to raise its dividend following heightened sales in the first nine months of the year, driven by its hemophilia injection, Hemlibra, and multiple sclerosis treatment, Ocrevus. Sales in the initial nine months climbed to 44.98 billion francs, up from 44.05 billion francs in the previous year, attributed to growth in both pharmaceutical and diagnostics divisions. Excluding currency movements, sales rose by 6%. Sales in the pharmaceutical and diagnostics sectors increased by 7% and 5%, respectively, in constant currencies. Roche confirmed its full-year outlook, anticipating high single-digit growth in core earnings per share in constant currencies, excluding the impact of tax disputes in 2023. It continues to expect sales growth to remain in the mid-single-digit range.